Latest Kyowa Kirin News & Updates

See the latest news and media coverage for Kyowa Kirin. We track all announcements, press releases, and industry mentions in real time, all in one place.

Company icon
Kyowa Kirin

Global specialty pharmaceutical company

kyowakirin.com
Headquarters
Chiyoda-ku, Japan
Company type
Public company
Number of employees
5,000–10,000

Latest news about Kyowa Kirin

Company announcements

  • Kyowa Kirin

    Kyowa Kirin initiates Japanese Phase 2 trial of ziftomenib

    First patient dosed in registrational trial for R/R NPM1-m AML. Plans regulatory filing post-trial. Collaborates with Kura Oncology.

  • Kyowa Kirin

    Kyowa Kirin discloses controlling shareholder details

    Provides information on parent Kirin Holdings' 55.22% ownership, relationships, transactions including 198,175 million yen loans, and independence measures.

  • Kyowa Kirin

    Kyowa Kirin resolves treasury shares disposal

    Disposes 99,648 shares at JPY 2,415 for restricted and performance-linked remuneration to executives. Payment on April 9, 2026.

  • Kyowa Kirin

    Kyowa Kirin corrects consolidated financial summary

    Fixes error in purchase of property, plant and equipment in cash flows for Fiscal 2025. Corrections underlined in red.

Unlock all announcements with a

Media coverage

  • MSN

    Kyowa Kirin, Kura launch Japan trial for targeted AML drug

    Kyowa Kirin and Kura Oncology have initiated a Japanese Phase II registrational trial of ziftomenib, an oral menin inhibitor, in adults with relapsed or refractory...

  • Markets Insider

    Kyowa Kirin and Kura Oncology Initiate Japanese Phase 2 Registration-Directed Trial of Ziftomenib in R/R NPM1-m AML

    Ziftomenib was approved by the U.S. Food and Drug Administration (FDA) in November 2025 for the treatment of adult patients with R/R NPM1 -m AML...

  • 日刊薬業

    Good results in international P3 for CLL/SLL targets

    Japan Eli Lilly announced on the 20th regarding the anticancer agent "Jayperca" (generic name = pirtobrutinib), an international collaborative study conducted targeting patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)... Regarding viewing restrictions for non-members This article is for members only. If you register as a member, you can read to the end...

  • 日刊薬業

    Selective type 1 TNF receptor inhibitor, domestic P1 started

    Asahi Kasei Therapeutics and Peptidream announced on the 20th that they have started a phase 1 clinical trial in Japan for the selective type 1 TNF receptor inhibitor "AK1940" (development code) created through the joint research of both companies. Autoimmune diseases… Regarding viewing restrictions for non-members This article is for members only. If you register as a member, you can read it to the end...

Unlock all articles with a

Never miss news about Kyowa Kirin

Track Kyowa Kirin and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Kyowa Kirin competitors & trending companies

Browse news for competitors to Kyowa Kirin and other trending companies.